Wells Fargo Maintains a Buy Rating on Merck & Company (MRK)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Merck & Company (MRKResearch Report) today and set a price target of $90.00. The company’s shares closed last Tuesday at $79.15.

According to, Bansal is a 4-star analyst with an average return of 7.6% and a 52.9% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Eli Lilly & Co, and Bristol Myers.

Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $93.10, which is a 17.4% upside from current levels. In a report issued on March 17, Mizuho Securities also maintained a Buy rating on the stock with a $100.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.52 billion and net profit of $3.76 billion. In comparison, last year the company earned revenue of $10.95 billion and had a GAAP net loss of $2.09 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Read More on MRK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More